Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

British Journal of Haematology

Volumn 128, Issue 5, 2005, Pages 690-697

  Kröger, Nicolaus ^a   Zabelina, Tatjana ^a   Schieder, Heike ^a   Panse, Jens ^a   Ayuk, Francis ^a   Stute, Norbert ^a   Fehse, Natalja ^a   Waschke, Olga ^a   Fehse, Boris ^a   Kvasnicka, Hans Michael ^b   Thiele, Jürgen ^b   Zander, Axel ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Donor lymphocyte infusion; Graft failure; Graft versus host disease; Myelofibrosis; Reduced intensity conditioning

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYELOFIBROSIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL; VEIN OCCLUSION;

ADULT; ANTILYMPHOCYTE SERUM; BLOOD TRANSFUSION, AUTOLOGOUS; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MYELOFIBROSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 20044391419     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05373.x     Document Type: Article

References (35)

1. Barosi, G., Berzunuini, C., Liberato, L.N., Costa, A., Polino, G. & Ascari, E. (1988) A prognostic classification of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 70, 397-401.
2. Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G. & Tura, S. (1999) The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 104, 730-737.
3. Bauermeister, D.E. (1971) Quantitation of bone marrow reticulin - a normal range. American Journal of Clinical Pathology, 56, 24-31.
4. Bearman, S.I., Appelbaum, F.R., Buckner, C.D., Petersen, F.B., Fisher, L.D., Clift, R.A. & Thomas, E.D. (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. Journal of Clinical Oncology, 6, 1562-1568.
5. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 58, 2440-2447.
6. Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. & Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. British Journal of Haematology, 108, 430-433.
7. Cervantes, F., Barosi, G., Demory, J.L., Reilly, J., Guarnone, R., Dupriez, B., Pereira, A. & Montserrat, E. (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 102, 684-690.
8. Cervantes, F., Rovira, M., Urbano-Ispizua, A., Rozman, M., Carreras, E. & Montserrat, E. (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplantation, 26, 697-699.
9. Daly, A., Song, K., Nevill, T., Nantel, S., Toze, C., Hogge, D., Forrest, D., Lavoie, J., Sutherland, H., Shepherd, J., Hasegawa, W., Lipton, J., Messner, H. & Kiss, T. (2003) Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplantation, 32, 35-40.
10. Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 3912-3918.
11. Devine, S.M., Hoffman, R., Verma, A., Shah, R., Bradlow, B.A., Stock, W., Maynard, V., Jessop, E., Peace, D., Huml, M., Thomason, D., Chen, Y.H. & van Besien, K. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 2255-2258.
12. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Baulers, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
13. Fehse, B., Chukhlovin, A., Kuhlcke, K., Marinetz, O., Vorwig, O., Renges, H., Kruger, W., Zabelina, T., Dudina, O., Finckenstein, F.G., Kroger, N., Kabisch, H., Hochhaus, A. & Zander, A.R. (2001) Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. Journal of Hematotherapy and Stem Cell Research, 10, 419-425.
14. Giralt, S., Thall, P.F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B.S., Anderlini, P., Gajewski, J., Kornblau, S., Andreeff, M., Przepiorka, D., Oeno, N.T., Molldrem, J. & Champlin, R. (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 97, 631-637.
15. Gooley, T.A., Leisenring, W., Crowley, J. & Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695-706.
16. Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
17. Hertenstein, B. (2002) Non-myeloablative stem cell transplantation for myeloid metaplasia with myelofibrosis. A survey from the Chronic Leukemia Working Party. Blood, 100, 253 (abstract).
18. Hessling, J., Kroger, N., Werner, M., Zabelina, T., Hansen, A., Kordes, U., Ayuk, F.A., Renges, H., Panse, J., Erttmann, R. & Zander, A.R. (2002) Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 119, 769-772.
19. Kroger, N., Zabelina, T., Kruger, W., Renges, H., Stute, N., Durken, M., Graf, v.F., Erttmann, R., Kabisch, H., Schafhausen, P., Jaburg, N., Loliger, C. & Zander, A.R. (2001) Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Annals of Hematology, 80, 209-215.
20. Kvasnicka, H.M., Thiele, J., Werden, C., Zankovich, R., Diehl, V. & Fischer, R. (1997) Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer, 80, 708-719.
21. Kvasnicka, H.M., Thiele, J., Regn, C., Zankovich, R., Diehl, V. & Fischer, R. (1999) Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis. Annals of Hematology, 78, 65-72.
22. Manoharan, A., Horsley, R. & Pitney, W.R. (1979) The reticulin content of bone marrow in acute leukaemia in adults. British Journal of Haematology, 43, 185-190.
23. McDonald, G.B., Hinds, M.S., Fisher, L.D., Schoch, H.G., Wolford, J.L., Banaji, M., Hardin, B.J., Shulman, H.M. & Clift, R.A. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Annals of Internal Medicine, 118, 255-267.
24. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
25. Mesa, R.A., Silverstein, M.N., Jacobsen, S.J., Wollan, P.C. & Tefferi, A. (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology, 61, 10-15.
26. Messinezy, M., Pearson, T.C., Prochazka, A. & Wetherley-Mein, G. (1985) Treatment of primary proliferative polycythaemia by vene-section and low dose busulphan: retrospective study from one centre. British Journal of Haematology, 61, 657-666.
27. Nagler, A., Aker, M., Or, R., Naparstek, E., Varadi, G., Brautbar, C. & Slavin, S. (2001) Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Experimental Hematology, 29, 362-370.
28. Najean, Y., Dresch, C. & Rain, J.D. (1994) The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. British Journal of Haematology, 86, 233-235.
29. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825-828.
30. Rondelli, D (2003) Non-myeloablative allogeneic HSCT in high-risk patients with myelofibrosis. Blood, 102.
31. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
32. Thiele, J., Kvasnicka, H.M., Schmitt-Graeff, A., Zankovich, R. & Diehl, V. (2002) Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. American Journal of Hematology, 70, 283-291.
33. Thiele, J., Kvasnicka, H.M., Schmitt-Graeff, A. & Diehl, V. (2003) Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology, 43, 470-479.
34. Visani, G., Finelli, C., Castelli, U., Petti, M.C., Ricci, P., Vianelli, N., Gianni, L., Zuffa, E., Spiriti, MAA, Latagliata, R, Pileri, S, Magrini, U, Gugliotta, L, Morra, E, Bernasconi, C, Mandelli, F, Tura, S. (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. British Journal of Haematology, 75, 4-9.
35. Zander, A.R., Kroger, N., Schleuning, M., Finke, J., Zabelina, T., Beelen, D., Schwerdtfeger, R., Baurmann, H., Bornhauser, M., Ehninger, G., Fauser, A.A., Kiehl, M., Trenschel, R., Ottinger, H.D., Bertz, H., Berger, J., Kolb, H.J. & Schaefer, U.W. (2003) ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplantation, 32, 355-361.